PERSPECTIVE THERAPEUTICS, INC. Earnings Per Share (Diluted)
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Earnings Per Share (Diluted) of -$0.22 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-10
- PERSPECTIVE THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.22.
- PERSPECTIVE THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.25.
- PERSPECTIVE THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.50.
- PERSPECTIVE THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.35.
- PERSPECTIVE THERAPEUTICS, INC. earnings per share, diluted for fiscal 2025 was -$1.40.
- PERSPECTIVE THERAPEUTICS, INC. earnings per share, diluted for fiscal 2024 was -$1.23.
- PERSPECTIVE THERAPEUTICS, INC. earnings per share, diluted for fiscal 2023 was -$1.74.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$0.22 10-Q · filed 2026-08-10 | -$0.47 10-Q · filed 2026-08-10 | -$0.91 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$1.25 derived: net income ÷ weighted average shares · filed 2026-08-10 | |
| 2026-03-31 | -$0.25 10-Q · filed 2026-05-11 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$1.07 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$1.36 derived: net income ÷ weighted average shares · filed 2026-08-10 | |
| 2025-12-31 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$0.85 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.14 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$1.40 10-K · filed 2026-03-16 | |
| 2025-09-30 | -$0.35 10-Q · filed 2025-11-10 | -$0.64 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$0.89 10-Q · filed 2025-11-10 | -$1.45 derived: net income ÷ weighted average shares · filed 2026-08-10 | |
| 2025-06-30 | -$0.29 10-Q · filed 2026-08-10 | -$0.54 10-Q · filed 2026-08-10 | -$1.10 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$1.32 derived: net income ÷ weighted average shares · filed 2026-08-10 | |
| 2025-03-31 | -$0.25 10-Q · filed 2026-05-11 | -$0.82 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$1.03 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$1.21 derived: net income ÷ weighted average shares · filed 2026-08-10 | |
| 2024-12-31 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$0.78 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$0.97 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.23 10-K · filed 2026-03-16 | |
| 2024-09-30 | -$0.21 10-Q · filed 2025-11-10 | -$0.39 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$0.62 10-Q · filed 2025-11-10 | -$1.19 derived: net income ÷ weighted average shares · filed 2026-04-16 | |
| 2024-06-30 | -$0.18 10-Q · filed 2025-08-13 | -$0.41 10-Q · filed 2025-08-13 | -$1.01 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.37 derived: net income ÷ weighted average shares · filed 2026-04-16 | |
| 2024-03-31 | -$0.25 10-Q · filed 2025-05-12 | -$0.02 10-Q · filed 2024-05-15 | -$0.95 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.34 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.75 derived: net income ÷ weighted average shares · filed 2026-04-16 |
| 2023-12-31 | -$0.88 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.25 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.64 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.74 10-K/A · filed 2025-03-28 | |
| 2023-09-30 | -$0.37 10-Q · filed 2024-11-12 | -$0.77 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$0.83 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$0.40 10-Q · filed 2024-08-13 | -$0.45 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |